Opaleye Management Inc.
13F Reported Value
ⓘ$759.2M
Holdings
54
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Opaleye Management Inc. disclosed 54 positions worth $759.2M in its Form 13F-HR for Q1 2026, led by $HROW (HARROW, INC.) at 13.2% of the equity portfolio, followed by $LQDA and $ETON. During the quarter the fund opened 8 new positions and exited 9 — including a new stake in $EDIT and a full exit from $ALKS. The portfolio is most concentrated in Healthcare (98.5% of disclosed assets). All figures are sourced directly from Opaleye Management Inc.’s Form 13F-HR filing with the SEC under CIK 1595855.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 41.6#1,885
Quality
$99.9M2,832,230 sh - 37.4#2,056
Quality
$88.8M2,545,000 sh - 51.9#1,374
Quality
$70.6M2,860,000 sh - —
Quality
$39.6M500,000 sh - 30.3
Quality
$35.3M123,000 sh - —
Quality
$32.8M390,000 sh - —
Quality
$26.9M421,000 sh - —
Quality
$25.7M1,430,000 sh - 28.0
Quality
$24.1M1,312,615 sh - 53.4
Quality
$22.8M700,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 HARROW, INC.$HROW | 41.6#1,885 | $99.9M | 2,832,230 |
 Liquidia Corp$LQDA | 37.4#2,056 | $88.8M | 2,545,000 |
 Eton Pharmaceuticals, Inc.$ETON | 51.9#1,374 | $70.6M | 2,860,000 |
 Sol-Gel Technologies Ltd.$SLGL | — | $39.6M | 500,000 |
 RHYTHM PHARMACEUTICALS, INC.$RYTM | 30.3 | $35.3M | 123,000 |
 Apogee Therapeutics, Inc.$APGE | — | $32.8M | 390,000 |
 Disc Medicine, Inc.$IRON | — | $26.9M | 421,000 |
 UroGen Pharma Ltd.$URGN | — | $25.7M | 1,430,000 |
 CRESCENT BIOPHARMA, INC.$CBIO | 28.0 | $24.1M | 1,312,615 |
 Stoke Therapeutics, Inc.$STOK | 53.4 | $22.8M | 700,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Opaleye Management Inc.'s 54 positions.
Showing top 10 of 54 holdings.
Sector Allocation
Healthcare
$748.2M
Materials
$11.1M
Full Holdings — Opaleye Management Inc. (Q1 2026)
All 54 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $HROW | HARROW, INC. | $99.9M | 13.2% | -27% | 41.6 |
| 2 | $LQDA | Liquidia Corp | $88.8M | 11.7% | +5% | 37.4 |
| 3 | $ETON | Eton Pharmaceuticals, Inc. | $70.6M | 9.3% | +0% | 51.9 |
| 4 | $SLGL | Sol-Gel Technologies Ltd. | $39.6M | 5.2% | +10% | — |
| 5 | $RYTM | RHYTHM PHARMACEUTICALS, INC. | $35.3M | 4.7% | -63% | 30.3 |
| 6 | $APGE | Apogee Therapeutics, Inc. | $32.8M | 4.3% | +0% | — |
| 7 | $IRON | Disc Medicine, Inc. | $26.9M | 3.5% | +111% | — |
| 8 | $URGN | UroGen Pharma Ltd. | $25.7M | 3.4% | +433% | — |
| 9 | $CBIO | CRESCENT BIOPHARMA, INC. | $24.1M | 3.2% | +11% | 28 |
| 10 | $STOK | Stoke Therapeutics, Inc. | $22.8M | 3.0% | +1% | 53.4 |
| 11 |  $CATX | Perspective Therapeutics, Inc. | $19.5M | 2.6% | +295% | — |
| 12 |  $RZLT | Rezolute, Inc. | $19.2M | 2.5% | +0% | — |
| 13 |  $MGTX | MeiraGTx Holdings plc | $18.4M | 2.4% | +443% | — |
| 14 |  $TGTX | TG THERAPEUTICS, INC. | $17.8M | 2.3% | +0% | 68.4 |
| 15 |  $SNWV | SANUWAVE Health, Inc. | $17.0M | 2.2% | +0% | 59.3 |
| 16 |  $EWTX | Edgewise Therapeutics, Inc. | $15.8M | 2.1% | +0% | — |
| 17 |  $ACOG | Alpha Cognition Inc. | $14.1M | 1.9% | +24% | — |
| 18 |  $ANNX | Annexon, Inc. | $12.9M | 1.7% | -10% | — |
| 19 |  $ALMS | ALUMIS INC. | $12.1M | 1.6% | +3% | 9.2 |
| 20 |  $CDXS | CODEXIS, INC. | $11.1M | 1.5% | -0% | 11.3 |
| 21 |  $PTGX | Protagonist Therapeutics, Inc | $10.5M | 1.4% | -5% | 24.8 |
| 22 |  $RVMD | Revolution Medicines, Inc. | $9.7M | 1.3% | +0% | — |
| 23 |  $XOMA | XOMA Royalty Corp | $9.4M | 1.2% | +3% | 74 |
| 24 |  $QTTB | Q32 Bio Inc. | $8.1M | 1.1% | +489% | 23.1 |
| 25 |  $MBX | MBX Biosciences, Inc. | $7.8M | 1.0% | +0% | — |
| 26 |  $RLMD | RELMADA THERAPEUTICS, INC. | $6.5M | 0.9% | +0% | — |
| 27 |  $CGON | CG Oncology, Inc. | $6.4M | 0.8% | -77% | 28 |
| 28 |  $JBIO | Jade Biosciences, Inc. | $6.0M | 0.8% | +0% | — |
| 29 |  $OCUL | OCULAR THERAPEUTIX, INC | $5.1M | 0.7% | -62% | 12.8 |
| 30 |  $ASRT | Assertio Holdings, Inc. | $5.1M | 0.7% | -7% | 27.2 |
| 31 |  $EDIT | Editas Medicine, Inc. | $4.8M | 0.6% | NEW | 10.8 |
| 32 |  $STRO | SUTRO BIOPHARMA, INC. | $4.7M | 0.6% | +0% | 30.1 |
| 33 |  $DERM | Journey Medical Corp | $4.5M | 0.6% | -2% | 26.4 |
| 34 |  $VYGR | Voyager Therapeutics, Inc. | $4.4M | 0.6% | -4% | 5.5 |
| 35 |  $TRVI | Trevi Therapeutics, Inc. | $4.1M | 0.5% | +0% | — |
| 36 |  $TECX | Tectonic Therapeutic, Inc. | $3.8M | 0.5% | -43% | — |
| 37 |  $CABA | Cabaletta Bio, Inc. | $3.7M | 0.5% | +53% | — |
| 38 |  $BDSX | BIODESIX INC | $3.5M | 0.5% | NEW | 32.3 |
| 39 |  $RCKT | ROCKET PHARMACEUTICALS, INC. | $3.4M | 0.5% | +0% | — |
| 40 |  $ZNTL | Zentalis Pharmaceuticals, Inc. | $3.3M | 0.4% | +1% | — |
| 41 |  $NTLA | Intellia Therapeutics, Inc. | $3.1M | 0.4% | NEW | 24.5 |
| 42 |  $FBIO | Fortress Biotech, Inc. | $2.9M | 0.4% | -4% | 61.8 |
| 43 |  $IRD | Opus Genetics, Inc. | $2.3M | 0.3% | +0% | — |
| 44 |  $RIGL | RIGEL PHARMACEUTICALS INC | $1.9M | 0.3% | +0% | 73.9 |
| 45 |  $AVIR | Atea Pharmaceuticals, Inc. | $1.7M | 0.2% | +79% | — |
| 46 |  $LYEL | Lyell Immunopharma, Inc. | $1.6M | 0.2% | NEW | 3.6 |
| 47 |  $ENTA | ENANTA PHARMACEUTICALS INC | $1.6M | 0.2% | +67% | 15.5 |
| 48 |  $NXTC | NextCure, Inc. | $1.5M | 0.2% | NEW | — |
| 49 |  $FDMT | 4D Molecular Therapeutics, Inc. | $1.0M | 0.1% | NEW | 23.2 |
| 50 | $CATX | Perspective Therapeutics, Inc. | $834,000 | 0.1% | NEW | — |
| 51 |  $PLX | Protalix BioTherapeutics, Inc. | $737,800 | 0.1% | -86% | 67 |
| 52 |  $BBOT | BridgeBio Oncology Therapeutics, Inc. | $476,874 | 0.1% | NEW | — |
| 53 |  $LBRX | LB PHARMACEUTICALS INC | $357,718 | 0.1% | NEW | — |
| 54 |  $ADGM | Adagio Medical Holdings, Inc. | $21,211 | 0.0% | -83% | — |
New Positions (8)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Opaleye Management Inc. including:
Track Opaleye Management Inc.'s Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Opaleye Management Inc. and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Opaleye Management Inc.
13F Pro is an AI hedge fund tracker and stock research platform. For Opaleye Management Inc. (SEC CIK: 1595855), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Opaleye Management Inc.'s portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.